Three Vaccine Developers Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired Three Vaccine Developers, a pharmacy business in the United States, for up to $3.8 billion. The targets are clinical-stage infectious disease vaccine developers focused on areas such as shingles and broader immunization pipelines, strengthening Eli Lilly acquisitions in vaccines. Eli Lilly acquisitions also expand infectious disease capabilities beyond its core portfolio, supporting a platform acquisition strategy in healthcare M&A. The strategic acquisition is structured as a platform acquisition with total consideration reported up to $3.8B, including an upfront payment and milestone-based amounts, and is currently announced with deal terms under negotiation.